A Cell Therapy Frontier: Macrophages Step Up to Reverse Liver Failure

LONDON – November 05, 2026 – For the tens of thousands of people diagnosed with end-stage liver disease each year, modern medicine offers a grim ultimatum: secure a scarce donor organ, or prepare for the end. With median survival hovering around two years and no approved disease-modifying therapies on the market, decompensated cirrhosis remains one of the most glaring voids in our healthcare system. It is a disease defined by systemic inequity, where survival often depends on the geographic and socioeconomic luck required to navigate the transplant waitlist.

Now, a clinical-stage biopharmaceutical company is attempting to rewrite that narrative, shifting the paradigm from organ replacement to organ repair.

Resolution Therapeutics today announced highly anticipated six-month interim data from its Phase I/II EMERALD trial. The study is evaluating RTX001, an investigational autologous engineered regenerative macrophage therapy, in patients with end-stage liver disease (ESLD). The results, which are being presented as a late-breaker at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting in Denver, suggest that reprogramming a patient's own immune cells could significantly alter the fatal trajectory of liver failure.

According to the interim analysis, RTX001 demonstrated a 42% relative risk reduction in a composite endpoint of death, liver transplant, or hepatic decompensation when compared to an external natural history control group. While the sample size is small—and the use of an external control demands rigorous journalistic and scientific scrutiny—the biological signal is undeniable.

Reprogramming the Body’s Cleanup Crew

To understand the promise of RTX001, one must look at the dual nature of macrophages. In a healthy liver, these white blood cells act as the body’s cleanup crew, responding to injury by triggering inflammation and laying down scar tissue. In chronic liver disease, this process goes into overdrive, leading to the dense, suffocating fibrosis that characterizes cirrhosis.

Resolution Therapeutics, a spinout from the University of Edinburgh, extracts monocytes from a patient's blood and engineers them using mRNA to express IL-10 and MMP-9. This genetic modification effectively flips the macrophages' biological switch, transforming them from inflammatory instigators into anti-fibrotic remodelers. Once infused back into the patient, these engineered cells are designed to dissolve scar tissue and create a permissive environment for the liver to regenerate.

“These interim results show RTX001 has the potential to change the trajectory for patients with end-stage liver disease, who currently have very limited treatment options beyond liver transplantation,” said Amir Hefni, Chief Executive Officer of Resolution Therapeutics. “These findings further support our belief in the transformative opportunity with Regenerative Macrophage Therapy to redefine how this and other inflammatory and fibrotic diseases are treated.”

The EMERALD interim data backs up the biological theory. Pharmacodynamic biomarker analyses revealed reduced activity in key inflammatory pathways and significant drops in markers of fibrogenesis.

Crucially, the therapy appears safe and accessible. Unlike CAR-T cell therapies used in oncology, which require toxic pre-conditioning and lymphodepletion that can leave patients hospitalized and immunocompromised, RTX001 requires no such regimen. Patients in the EMERALD trial received up to four doses with stable peri-infusion vital signs, no infusion-related serious adverse reactions, and no severe adverse events related to the treatment. This profile opens the door to outpatient, community-based delivery—a vital logistical advantage for a frail patient population.

The Statistical Caveat: Grading on an External Curve

While the 42% relative risk reduction is a striking headline, the architecture of the trial warrants a closer look. The interim analysis compared the first nine patients treated with RTX001 in the open-label EMERALD trial against 21 patients receiving standard-of-care in the OPAL study, an observational natural history cohort serving as an external control.

In the treated group, two of nine patients (22%) experienced death, transplant, or hepatic decompensation within six months, compared to eight of 21 (38%) in the OPAL cohort. Death or transplant alone occurred in 11% of the RTX001 group versus 19% in the control.

External control arms are notoriously tricky. While sometimes ethically necessary in severe diseases where a placebo arm is difficult to justify, they inherently lack the randomization and blinding that filter out hidden biases. Differences in baseline health, subtle variations in standard-of-care across different clinical sites, and the psychological "placebo effect" of receiving an experimental cell therapy can all skew the data.

“When you compare a highly monitored, actively treated Phase I cohort against an observational registry, you are almost always going to see an amplified treatment effect,” noted an independent biostatistician familiar with hepatology trial designs. “The biological markers of reduced fibrosis are highly encouraging, but a 42% risk reduction in a cohort of nine patients must be treated as a hypothesis-generating signal, not definitive proof. The FDA will demand a randomized, controlled environment to validate this.”

Resolution Therapeutics is not operating in a vacuum, however. RTX001 builds on the University of Edinburgh’s MATCH trial, which evaluated non-engineered macrophages in patients with less advanced liver disease. That study reported a hazard ratio of 0.39 for death or transplant over four years.

Professor Jonathan Fallowfield, Chair of Translational Liver Research at the University of Edinburgh and Chief Investigator of EMERALD, emphasized this continuity. “Importantly, the results are broadly consistent with the clinical outcomes reported at four years in the University of Edinburgh's MATCH trial... These interim data provide encouraging evidence that RTX001 may improve outcomes in this highly vulnerable patient population.”

An Alternative to the Transplant Lottery

The broader pharmaceutical pipeline for liver disease has largely abandoned patients with decompensated cirrhosis. Blockbuster GLP-1 receptor agonists and emerging small-molecule therapies like FXR and THR-β agonists are currently dominating the metabolic dysfunction-associated steatohepatitis (MASH/NASH) landscape. However, these drugs are primarily designed to halt early-stage fibrosis. Once a patient's liver crosses the threshold into end-stage failure, these metabolic interventions offer little salvation.

This leaves over 50,000 Americans dying annually from ESLD, a condition that ranks as the ninth leading cause of death nationally. The transplant system, while a marvel of modern surgery, is fundamentally constrained by mathematics: there are simply not enough donor organs to meet the demand. Furthermore, the transplant evaluation process often inherently disadvantages those without robust social support networks, comprehensive insurance, or proximity to major transplant centers.

If engineered macrophages can reliably halt or reverse hepatic decompensation, they offer something profoundly democratic: an off-the-shelf, scalable alternative to the transplant lottery.

Dr. Clifford Brass, Chief Medical Officer of Resolution Therapeutics, highlighted this potential. “Preliminary biomarker data show reduced inflammatory activity and lower markers of fibrogenesis... these findings are consistent with the engineered mechanism of RTX001 and highlight its potential to deliver profound patient impact.”

The Regulatory Crucible Awaits

The true test for Resolution Therapeutics will come not in the laboratories of Edinburgh, but in the regulatory corridors of Washington, D.C. The company has secured a pre-IND meeting with the U.S. Food and Drug Administration (FDA) scheduled for December 2026.

During this meeting, the company will seek to advance RTX001 into a planned U.S. pivotal trial. The FDA’s Center for Biologics Evaluation and Research (CBER) will scrutinize the manufacturing consistency of these autologous cells, the robustness of the external control comparison, and the durability of the six-month data. Given the severe unmet medical need, RTX001 may be a prime candidate for Regenerative Medicine Advanced Therapy (RMAT) designation, which could expedite its path to market.

For decades, the narrative of cell therapy has been almost exclusively tied to oncology—using engineered cells as assassins to hunt down cancer. Resolution Therapeutics is pioneering a different narrative, utilizing engineered cells as architects to rebuild failing organs. The EMERALD trial has fully enrolled its 15 patients, with a primary analysis slated for 2028. Until then, the hepatology community, and thousands of patients waiting for a liver that may never come, will be watching closely.